Overview
- The company is slated to release fiscal Q3 2025 results on October 21, with projections near $2.5 billion in revenue and expectations for some margin pressure from higher component costs and R&D spending.
- Wall Street remains positive ahead of the print, with Morgan Stanley reiterating a Buy and a $650 target and BTIG maintaining a Buy with a $571 target.
- Management’s full‑year outlook calls for 15.5%–17% worldwide procedure growth and non‑GAAP gross margins of 66%–67% of revenue.
- Operational metrics remain robust, with 10,488 da Vinci systems installed globally in Q2 2025 (up 14% year over year) and procedures rising 17% year over year.
- Shares have fallen roughly 25% from recent highs, and some commentators suggest diversified medical‑device exposure such as Medtronic for investors seeking lower volatility.